Treatment selection for esophageal cancer: evaluation from a nationwide database
- 95 Downloads
Most elderly patients poorly tolerate the standard treatment for esophageal cancer; however, little information is available regarding the appropriateness of non-standard esophageal cancer treatments for those patients. This study aims to analyze the treatment costs and completion rates of patients undergoing a real-world treatment for esophageal cancer to elucidate the treatment selection and its quality.
Materials and methods
We analyzed treatment costs and completion rates for patients with esophageal cancer and analyzed these data relative to patient age and center volumes. Patients with esophageal cancer [UICC, TMN, Clinical stage II/III (excluding T4)] who were diagnosed in 2013 were analyzed. Patients were classified into five groups defined as follows: surgical therapy, chemotherapy, concurrent chemoradiotherapy (CCRT), modified concurrent chemoradiotherapy (mCRT), and radiotherapy (RT).
Mean and median age of patients who received surgery and CCRT were comparable; however, patients who underwent mCRT and RT tended to be older. Medical costs associated with surgery were higher than costs associated with other non-surgical treatments. Cost and completion rate of chemoradiotherapy did not differ between CCRT and mCRT; however, both had higher completion rates compared to that of RT. Surgical expenses tended to be the highest in low-volume centers and the lowest in high-volume centers.
Treatment of esophageal cancer at high-volume centers seems well balanced compared with medium- to low-volume centers. mCRT was widely performed and comparable in medical cost to CCRT, although additional clinical impacts were unclear.
KeywordsEsophageal cancer Chemoradiotherapy Elderly Costs of care Hospital-based cancer registries
Diagnosis Procedure Combination
Modified concurrent chemoradiotherapy
Designated Cancer Care Hospitals
Hospital-based cancer registries
Compliance with ethical standards
Authors declare that our work conforms to the guidelines set forth in the Helsinki Declaration of 1975, as revised in 2000, concerning Human and Animal Rights, and that they followed the policy concerning Informed Consent.
Conflict of interest
Naoki Sakakibara, Fumio Nagashima, and Takahiro Higashi have no conflicts of interest. Yasuo Hamamoto has conflicts of interest to declare with regard to this manuscript: Ono Pharmaceutical Co. Yuko Kitagawa has conflicts of interest to declare with regard to this manuscript: Ethicon, Ono Pharmaceutical Co., Taiho Pharma, Chugai Pharmaceutical co., Asahi Kasei Pharma, Otsuka Pharmaceutical Co., Kyowa Hakko Kirin Co., Daiichi Sankyo co., Takeda Pharmaceutical Co. Nippon Boehringer Ingelheim Co., Novartis Pharma., Pfeizer Japan, Merck Serono Co., Yakult Honsha co., Terumo Corporation, Torii Pharmaceutical Co., Astra Zeneca.
- 15.NationalComprehensiveCancerNetwork. NCCN clinical practice guidelines in oncology esophageal and esophagogastric junction cancers: NCCN. org; Version 2. 2016.Google Scholar